Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884387 | 1.00 | TMPRSS4 (0.41) | TMPRSS4EGLN1HPGDMEN1KMT2A | |
| SCHEMBL21884601 | 0.80 | TMPRSS4 (0.44) | TMPRSS4EGLN1MEN1KMT2AHSD17B10 | |
| SCHEMBL6619362 | 0.77 | ALOX5 (0.60) | TMPRSS4HPGDMEN1KMT2AALOX5 | |
| SCHEMBL21884385 | 0.76 | SCN9A (0.44) | TMPRSS4EGLN1HPGDKDM4EALDH1A1 | |
| SCHEMBL21884626 | 0.76 | TMPRSS4 (0.42) | TMPRSS4EGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL21884386 | 0.75 | TMPRSS4 (0.46) | TMPRSS4EGLN1MEN1KMT2AALDH1A1 | |
| SCHEMBL21884774 | 0.75 | GSK3B (0.48) | HPGDMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL21884511 | 0.74 | TMPRSS4 (0.44) | TMPRSS4P2RX1 | |
| SCHEMBL21884388 | 0.74 | TMPRSS4 (0.47) | TMPRSS4EGLN1MEN1KMT2AP2RX1 | |
| SCHEMBL21884643 | 0.73 | TMPRSS4 (0.51) | TMPRSS4P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | TMPRSS4 1380/4885EGLN1 1665/4885HPGD 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.